Eight years. Over three thousand participants. Zero ambiguity in the results. If you have ever second-guessed your PrEP routine, wondered whether switching between dosing styles was somehow weakening your protection, or just wanted science to finally back up what doctors have been saying for years โ the biggest HIV prevention study out of CROI 2026 was written for you.
The Study That Went the Distance
Eight years after it launched, the final results of a large French study offering participants a choice between daily or event-driven oral PrEP using tenofovir disoproxil/emtricitabine landed at CROI 2026. The conference, held in Denver in February, is the most significant gathering of HIV researchers on the planet. This was one of its most talked-about moments.
The findings confirmed that both daily and on-demand oral PrEP are safe and effective over the long term. Most of the 3,209 participants were gay or bisexual cisgender men. At any given point, roughly half were taking daily PrEP and half were on event-driven dosing โ though individuals switched frequently between the two. The results reinforce something that should be reshaping clinic conversations everywhere: people deserve a genuine choice of PrEP regimen.
Read that last part slowly. Not just one method. Not a hierarchy of options with a “correct” answer at the top. A genuine choice โ the kind your doctor, your pharmacist, and your own life circumstances should be shaping together.
Daily vs. On-Demand: What the Science Actually Settles
The debate between daily PrEP and on-demand dosing has been running for years, in clinical settings and group chats alike. On-demand PrEP โ sometimes called the 2:1:1 method โ involves taking a double dose two to twenty-four hours before sex, one pill twenty-four hours after, and another pill forty-eight hours after. Developed with the sexual patterns of gay men in mind, it has always had a passionate following among those who find daily medication either inconvenient or harder to maintain.
The PREVENIR study out of Paris, led by Jean-Michel Molina, put both approaches through their paces over nearly a decade. What emerged were high efficacy levels across every group: those who stayed on daily oral TDF/FTC, those who committed to on-demand 2:1:1 dosing, and those who moved between them depending on what life looked like at the time.
That last group is the headline. People who switched between methods saw no meaningful drop in protection. That finding should change how both patients and prescribers approach the conversation. Your PrEP routine is allowed to evolve with you.
Why This Matters Right Now
The PREVENIR results arrived at a moment when the broader landscape of HIV prevention is under real strain. Even before US funding cuts, PrEP coverage was far too low in most countries to make a meaningful dent in HIV incidence โ and the cuts have made things considerably worse. Around 42 people need to be on PrEP to prevent one HIV infection per year, a benchmark that only Australia, Denmark, Norway, and the UK were close to achieving by the end of 2024.
The numbers elsewhere are stark. PEPFAR cuts have since reduced PrEP access dramatically โ by 28% in South Africa, 58% in Zambia, and 98% in Nigeria. The global picture is sobering. Which is precisely why long-term efficacy data confirming that oral PrEP works reliably, flexibly, and safely over nearly a decade is more than reassuring. It is essential ammunition for the advocates, doctors, and community organisations fighting to keep access alive.
Closer to home, a gap still exists between who has access to PrEP and who uses it consistently. An eight-year study showing that consistent protection does not require a rigid, one-size-fits-all approach is exactly the kind of evidence that can move the needle on uptake. If the barrier for some gay men has been the perceived inflexibility of a daily pill, the PREVENIR data dismantles that barrier entirely.
What Comes Next for PrEP
Oral PrEP remains the most widely available option globally, but the prevention horizon is expanding fast. Twice-yearly lenacapavir was the big story of 2024 and 2025. Gilead Sciences’ capsid inhibitor was approved for PrEP last June after two clinical trials showed that injections every six months dramatically reduced HIV acquisition risk โ for cisgender women in Africa and for gay and bisexual men and gender-diverse people in the United States and six other countries.
The next frontier may push even further. PURPOSE 365 is studying intramuscular lenacapavir given once every 12 months. Unlike the six-month subcutaneous version, this is an intramuscular injection in the gluteus, examining a 3,000 milligram dose now in clinical trials. Pharmacokinetic data is expected by the end of 2026.
A once-yearly injection for HIV prevention. That is where the science is heading. But take a moment to appreciate what PREVENIR reaffirmed: the tools already in hand, used in a way that fits a person’s actual life, are extraordinarily powerful. The future is exciting. The present already works.
Frequently Asked Questions
Is on-demand PrEP as effective as daily PrEP for gay men?
Yes โ and now there are eight years of data to prove it. The PREVENIR study confirmed that both daily and on-demand oral PrEP are safe and highly effective over the long term for gay and bisexual men.
Can I switch between daily PrEP and on-demand PrEP?
According to PREVENIR, yes. Participants who switched frequently between the two methods maintained strong protection throughout the study, suggesting flexible switching does not compromise efficacy. That said, always loop in your doctor before changing your regimen.
What is the on-demand PrEP dosing schedule?
The 2:1:1 method works like this: two pills taken two to twenty-four hours before sex, one pill twenty-four hours after, and one pill forty-eight hours after. It is specifically recommended for people who have anal sex and is not currently advised for other populations โ so talk to a healthcare provider to find out whether it fits your situation.
The PREVENIR study is eight years of rigorous science delivering one clear message: you have options, those options work, and they work even when your life requires you to move between them. In a moment when HIV prevention infrastructure is under pressure globally, knowing that the tools we already have are genuinely reliable is news worth sharing. Stay informed, stay protected, and stay connected to the community conversations that matter most right here at Facetheboys.
